X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
metastasis (3) 3
cancer (2) 2
care and treatment (2) 2
index medicus (2) 2
lymphatic system (2) 2
melanoma (2) 2
oncology (2) 2
patients (2) 2
quality of life (2) 2
studies (2) 2
survival (2) 2
1333 (1) 1
1349 (1) 1
1523 (1) 1
292 (1) 1
625 (1) 1
71–80 years (1) 1
administration, oral (1) 1
alcohol (1) 1
analysis (1) 1
antigens (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
article (1) 1
biomarkers, tumor - genetics (1) 1
cancer therapies (1) 1
chemotherapy (1) 1
clinical trials (1) 1
comparative analysis (1) 1
cpg islands (1) 1
cutaneous melanoma (1) 1
cysts (1) 1
data processing (1) 1
disease (1) 1
disease progression (1) 1
disease-free survival (1) 1
dna mutational analysis (1) 1
drug administration schedule (1) 1
endoscopy (1) 1
eq-5d (1) 1
europe (1) 1
european-organization (1) 1
expression (1) 1
female (1) 1
gene expression (1) 1
gene mutations (1) 1
genetic predisposition to disease (1) 1
hematology, oncology and palliative medicine (1) 1
hospitals (1) 1
humans (1) 1
imidazoles - administration & dosage (1) 1
imidazoles - adverse effects (1) 1
imidazoles - therapeutic use (1) 1
immune system (1) 1
immunotherapy (1) 1
indoles - administration & dosage (1) 1
indoles - adverse effects (1) 1
indoles - therapeutic use (1) 1
intention to treat analysis (1) 1
interferon-alpha-2b (1) 1
ipilimumab (1) 1
life sciences (1) 1
long term (1) 1
lymph nodes (1) 1
mage-a3 antigen (1) 1
map kinase kinase kinases - antagonists & inhibitors (1) 1
map kinase kinase kinases - metabolism (1) 1
melanoma - drug therapy (1) 1
melanoma - genetics (1) 1
melanoma - mortality (1) 1
melanoma - secondary (1) 1
metastases (1) 1
mortality (1) 1
mutation (1) 1
ostomy (1) 1
oximes - administration & dosage (1) 1
oximes - adverse effects (1) 1
oximes - therapeutic use (1) 1
phenotype (1) 1
prospective studies (1) 1
protein kinase inhibitors - administration & dosage (1) 1
protein kinase inhibitors - adverse effects (1) 1
protein kinase inhibitors - therapeutic use (1) 1
proto-oncogene proteins b-raf - antagonists & inhibitors (1) 1
proto-oncogene proteins b-raf - genetics (1) 1
pyridones - administration & dosage (1) 1
pyridones - adverse effects (1) 1
pyridones - therapeutic use (1) 1
pyrimidinones - administration & dosage (1) 1
pyrimidinones - adverse effects (1) 1
pyrimidinones - therapeutic use (1) 1
questionnaire qlq-c30 (1) 1
rare disease (1) 1
reliability (1) 1
risk factors (1) 1
scores (1) 1
signal transduction (1) 1
signature (1) 1
skin cancer (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Journal Article
BMJ Case Reports, ISSN 1757-790X, 2010, Volume 2010, Issue mar11 1, pp. bcr0720092116 - bcr0720092116
In recent years the prognosis for oesophageal squamous cell carcinoma patients has improved. Together with this improvement, the occurrence of second primary... 
Lymphatic system | Ostomy | Surgery | Mortality | Alcohol | Metastasis | Endoscopy | Patients | Long term | Stomach cancer | Quality of life
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.